Troxerutin, capsules 300 mg 50 pcs

Troxerutin – venotonizing, angioprotective agent, bioflavonoid. It reduces capillary permeability and fragility, strengthens the vascular wall, improves microcirculation, has an anti-edema effect. Participates in the redox processes, blocks the hyaluronic acid of the cell membranes. < br>

increases the density of the vascular wall, reduces the exudation of the liquid part of the plasma and diapedesis of blood cells. Reduces inflammation in the vascular wall by limiting platelet adhesion to its surface.

The use of Troxerutin is possible both in the initial and in the later stages of the treatment of chronic venous insufficiency, it is possible to use as one of the components of complex treatment.

Pharmacokinetics

After oral administration the drug is absorbed from the gastrointestinal tract, Cmax in plasma is noted on average 2 hours after administration, therapeutic plasma levels are maintained for 8 hours.

Metabolized in the liver, partially excreted unchanged in the urine and bile.

< br>.

Indications

chronic venous insufficiency;
trophic disorders in chronic venous insufficiency (dermatitis, trophic ulcers);
varicose veins;
superficial thrombophlebitis, periphlebitis;
postthrombotic syndrome;
post-traumatic edema, hematomas;
haemorrhoids;
diabetic angiopathy, retinopathy.

Pharmacological effect

Troxerutin is a venotonic, angioprotective agent, bioflavonoid. Reduces the permeability and fragility of capillaries, strengthens the vascular wall, improves microcirculation, and has an anti-edematous effect. Participates in redox processes, blocks hyaluronic acid in cell membranes.

Increases the density of the vascular wall, reduces exudation of the liquid part of the plasma and diapedesis of blood cells. Reduces inflammation in the vascular wall, limiting the adhesion of platelets to its surface.

The use of Troxerutin is possible both in the initial and late stages of treatment of chronic venous insufficiency; it can be used as one of the components of complex treatment.

Pharmacokinetics

After oral administration, the drug is absorbed from the gastrointestinal tract, Cmax in plasma is observed on average 2 hours after administration, the therapeutic level in plasma is maintained for 8 hours.

Metabolized in the liver, partially excreted unchanged in urine and bile.

Special instructions

There is no experience with the use of the drug in children under 15 years of age.

When treating superficial thrombophlebitis or deep vein thrombosis, the use of Troxerutin Zentiva does not exclude the need to prescribe anti-inflammatory and antithrombotic therapy.

Impact on the ability to drive vehicles and operate machinery

Taking the drug Troxerutin does not affect motor and mental reactions, does not interfere with driving or operating machinery.

Active ingredient

Troxerutin

Composition

1 capsule contains:

active ingredient:

troxerutin 300 mg

Pregnancy

Contraindicated in the first trimester of pregnancy and during breastfeeding; in the second and third trimesters of pregnancy, it can only be used as prescribed by a doctor.

Contraindications

peptic ulcer of the stomach and duodenum, chronic gastritis (in the acute phase);
hypersensitivity to the drug.

With caution: the drug should be used (long-term use) in case of renal failure.

Side Effects

Headache, irritation of the gastrointestinal mucosa, allergic reactions in the form of skin rashes and itching.

Interaction

When used simultaneously, it enhances the effect of ascorbic acid on the structure and permeability of the vascular wall.

Overdose

In case of overdose, the following symptoms may appear: agitation, nausea, headache and flushing.

In case of overdose, patients should rinse their stomach, take activated charcoal, and consult a doctor. If necessary, carry out symptomatic treatment.

Storage conditions

In a place protected from light, at a temperature not exceeding 25 °C.

Shelf life

3 years.

Manufacturer

Ozon, Russia